SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

08 Aug 2024 Evaluate
The sales figure stood at Rs. 3875.20 millions for the June 2024 quarter. The mentioned figure indicates a growth of about 31.15% as compared to Rs. 2954.70 millions during the year-ago period.The Net Loss for the quarter ended June 2024 is Rs. -117.90 millions as compared to Net Profit of Rs. 538.60 millions of corresponding quarter ended June 2023A decline of 464.20 millions was observed in the OP in the quarter ended June 2024 from 753.40 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 3875.20 2954.70 31.15 3875.20 2954.70 31.15 12955.28 10029.71 29.17
Other Income 83.50 81.00 3.09 83.50 81.00 3.09 348.00 261.02 33.32
PBIDT 464.20 753.40 -38.39 464.20 753.40 -38.39 2192.52 1912.27 14.66
Interest 1.10 1.50 -26.67 1.10 1.50 -26.67 12.01 6.33 89.73
PBDT -112.50 751.90 -114.96 -112.50 751.90 -114.96 2344.77 1503.65 55.94
Depreciation 39.10 37.90 3.17 39.10 37.90 3.17 149.40 162.60 -8.12
PBT -151.60 714.00 -121.23 -151.60 714.00 -121.23 2195.37 1341.05 63.71
TAX -33.70 175.40 -119.21 -33.70 175.40 -119.21 580.28 348.12 66.69
Deferred Tax -141.20 0.70 -20271.43 -141.20 0.70 -20271.43 -9.03 -34.90 -74.13
PAT -117.90 538.60 -121.89 -117.90 538.60 -121.89 1615.09 992.93 62.66
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 11.98 25.50 -53.02 11.98 25.50 -53.02 16.92 19.07 -11.24

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×